Apoptosis induced by molecular targeting therapy in hematological malignancies
S Adachi, LM Leoni, DA Carson, T Nakahata - Acta haematologica, 2003 - karger.com
S Adachi, LM Leoni, DA Carson, T Nakahata
Acta haematologica, 2003•karger.comMolecular targeting therapies for hematological malignant diseases such as monoclonal
antibodies and small molecules have been reviewed. Imatinib mesylate (STI571) targets the
tyrosine kinase activity of the bcr-abl fusion protein in CML, and was superior to IFN-α plus
low-dose cytarabine in newly diagnosed chronic-phase CML in a phase III randomized
study. Imatinib induced apoptosis in bcr-abl-positive cells in vitro, and activates several
signaling pathways such as PI3K/Akt, STAT5 and Ras/MAPK. Combination therapies with …
antibodies and small molecules have been reviewed. Imatinib mesylate (STI571) targets the
tyrosine kinase activity of the bcr-abl fusion protein in CML, and was superior to IFN-α plus
low-dose cytarabine in newly diagnosed chronic-phase CML in a phase III randomized
study. Imatinib induced apoptosis in bcr-abl-positive cells in vitro, and activates several
signaling pathways such as PI3K/Akt, STAT5 and Ras/MAPK. Combination therapies with …
Abstract
Molecular targeting therapies for hematological malignant diseases such as monoclonal antibodies and small molecules have been reviewed. Imatinib mesylate (STI571) targets the tyrosine kinase activity of the bcr-abl fusion protein in CML, and was superior to IFN-α plus low-dose cytarabine in newly diagnosed chronic-phase CML in a phase III randomized study. Imatinib induced apoptosis in bcr-abl-positive cells in vitro, and activates several signaling pathways such as PI3K/Akt, STAT5 and Ras/MAPK. Combination therapies with imatinib and new strategies for downregulation of intracellular Bcr-Abl protein levels have also been investigated from the phenomenon of resistance to imatinib. Anti-CD20 (rituximab) became the first monoclonal antibody approved for the treatment of a relapsed/refractory follicular/low-grade NHL and promising results were obtained from a phase III randomized study. Although antibody-dependent cell-mediated cytotoxicity and complement-mediated cytotoxicity are likely to be the major effectors of B-cell depletion in vivo, direct cytotoxicity by CD20 monoclonal antibody on B-cell lines in vitro has been reported. Anti-CD33 (Mylotarg) and FLT3 inhibitors for AML have also been used in clinical trials and signaling pathways induced by these agents are under intensive investigation. Arsenic trioxide, like all-trans-retinoic acid (ATRA), downregulates promyelocytic leukemia protein/retinoic acid receptor-α (PML/RARα) fusion protein and induced apoptosis in APL cells, and promising results were obtained from ATRA-resistant APL patients. Finally we show our promising in vitro and in vivo data of R-etodolac (a non-steroidal anti-inflammatory drug lacking cyclooxygenase inhibitor activity) against chronic lymphocytic leukemia (CLL) cells.
![](https://scholar.google.com/scholar/images/qa_favicons/karger.com.png)